ImmunoGen, Inc. - Common Stock (NQ:IMGN)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Feb 9, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ImmunoGen, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 01, 2022

From ImmunoGen, Inc.

Via Business Wire

Short Volatility Alert: ImmunoGen, Inc. ↗

August 31, 2022

On Tuesday, shares of ImmunoGen, Inc. (NASDAQ: IMGN) experienced volatile short activity. After the activity, the stock price went down -0.86% to $5.75. The overall sentiment for IMGN has been...

Via Benzinga

ImmunoGen Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm

August 31, 2022

From ImmunoGen, Inc.

Via Business Wire

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 01, 2022

From ImmunoGen, Inc.

Via Business Wire

Recap: Immunogen Q2 Earnings ↗

July 29, 2022

Immunogen (NASDAQ:IMGN) reported its Q2 earnings results on Friday, July 29, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Immunogen: Q1 Earnings Insights ↗

May 06, 2022

Immunogen (NASDAQ:IMGN) reported its Q1 earnings results on Friday, May 6, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

July 29, 2022

Via Benzinga

Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update ↗

July 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

ImmunoGen Reports Recent Progress and Second Quarter 2022 Financial Results

July 29, 2022

From ImmunoGen, Inc.

Via Business Wire

Earnings Preview For Immunogen ↗

July 28, 2022

Immunogen (NASDAQ:IMGN) is set to give its latest quarterly earnings report on Friday, 2022-07-29. Here's what investors need to know before the announcement. Analysts estimate that Immunogen will...

Via Benzinga

Earnings Scheduled For July 29, 2022 ↗

July 29, 2022

Companies Reporting Before The Bell • Capital Product Partners (NASDAQ:CPLP) is expected to report quarterly earnings at $1.13 per share on revenue of $72.73 million.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 19, 2022

Gainers Talis Biomedical (NASDAQ:TLIS) shares moved upwards by 10.6% to $0.94 during Tuesday's after-market session. The company's market cap stands at $25.0 million.

Via Benzinga

ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2022 Operating Results

July 14, 2022

From ImmunoGen Inc.

Via Business Wire

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 01, 2022

From ImmunoGen, Inc.

Via Business Wire

ImmunoGen Announces Research Collaboration with Oxford BioTherapeutics to Develop Novel Antibody-Drug Conjugates

June 13, 2022

From ImmunoGen Inc.

Via Business Wire

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 01, 2022

From ImmunoGen, Inc.

Via Business Wire

Immunogen's Return On Capital Employed Overview ↗

May 31, 2022

According to Benzinga Pro data, during Q1, Immunogen (NASDAQ:IMGN) posted sales of $38.08 million. Earnings were up 35.05%, but Immunogen still reported an overall loss of $24.14 million.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 27, 2022

Via Benzinga

ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO

May 26, 2022

From ImmunoGen, Inc.

Via Business Wire

ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences

May 25, 2022

From ImmunoGen, Inc.

Via Business Wire

What's Going On With ImmunoGen Shares Today? ↗

May 23, 2022

ImmunoGen, Inc. (NASDAQ: IMGN) shares are trading flat at $3.57 after the company's Biologics License Application to treat ovarian cancer was accepted by the FDA with priority review.

Via Benzinga

ImmunoGen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review

May 23, 2022

From ImmunoGen

Via Business Wire

Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression

May 18, 2022

Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – Companies in the Ovarian Cancer market are spending a lot of R&D on vaccine development, therapies and studies. For the past 30...

Via FinancialNewsMedia

Topics Death

ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming H.C. Wainwright Global Investment Conference

May 10, 2022

From ImmunoGen, Inc.

Via Business Wire

ImmunoGen Reports Recent Progress and First Quarter 2022 Financial Results

May 06, 2022

From ImmunoGen, Inc.

Via Business Wire

Immunogen Earnings Preview ↗

May 05, 2022

Immunogen (NASDAQ:IMGN) is set to give its latest quarterly earnings report on Friday, 2022-05-06. Here's what investors need to know before the announcement. Analysts estimate that Immunogen will...

Via Benzinga

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 02, 2022

From ImmunoGen, Inc.

Via Business Wire

Earnings Scheduled For May 6, 2022 ↗

May 06, 2022

Companies Reporting Before The Bell • Brookfield Renewable (NYSE:BEP) is expected to report quarterly loss at $0.02 per share on revenue of $1.27 billion.

Via Benzinga

The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗

May 02, 2022

Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...

Via Benzinga

Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating

April 25, 2022

Palm Beach, FL – April 25, 2022 – FinancialNewsMedia.com News Commentary – The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer...

Via FinancialNewsMedia

Topics Intellectual Property

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.